Also known as: J.P. Morgan, JPMorgan
Groupama Asset Management acquired a new stake in AstraZeneca, while ING Groep NV trimmed its position, reflecting mixed institutional activity. Amundi, Janus Henderson, and Royal Bank of Canada significantly increased their holdings in the first quarter. Institutional investors and hedge funds own 20.35% of AstraZeneca's stock.
GLP-1 receptor agonists are linked to a higher risk of smell and taste disturbances, while poison control calls involving semaglutide have soared since 2021. The drugs produce significant weight loss and are reshaping U.S. food demand, with roughly one in eight adults now taking them.
Institutional investors disclosed major changes to their AbbVie holdings as the stock hovers near record levels. AbbVie maintains a Moderate Buy analyst consensus with a $268.10 price target, buoyed by strong quarterly earnings and a newly declared dividend.
BioNTech faces mixed analyst views as Bernstein initiates with a cautious Market Perform rating, while the company secures FDA Fast Track designation for BNT113 and prepares for a shareholder vote on capital restructuring and leadership transition.
Analysts updated ratings on healthcare stocks: Ultragenyx remains Strong Buy, Immutep downgraded to Hold, BridgeBio gets Buy. American Well and Baxter stay Hold. Upside ranges from 11% to 154%.
JPMorgan downgraded Blue Jet Healthcare to Underweight with a ₹330 target price, citing weak contrast media execution, bempedoic acid competitive threats, and a thin late-stage pipeline with no launches expected for two years.
Moderna reported Q4 revenue of $678 million, beating analyst estimates, while posting a narrower-than-expected loss of $2.11 per share. The results came as the FDA refused to review the company's mRNA flu vaccine application.
